, (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative. Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025Vancouver, British Columbia--(Newsfile Corp. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. 2 based on 2 Stage Free Cash Flow to Equity. – May 31, 2022) – NervGen Pharma Corp. NervGen had cash and investments of $14. (TSX-V: NGEN) (OTCQX: NGENF). 5 million from the exercise of stock options and common share purchase warrants. 1. U. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. View real-time stock prices and stock quotes for a full financial overview. Financial Highlights. August 9, 2023 at 8:30 AM · 10 min read. 19 at the beginning of 2023. The company has also granted 2,892,000 incentive stock options to Mr. ,. 1 million as of June 30, 2023, compared to $22. Vancouver - NervGen Pharma Corp. - July 14, 2022) - NervGen Pharma Corp. 6 million. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 in the. This was offset by approximately $3. The company’s lead target. S. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that renowned neuroscientist, Dr. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. Today ||| 52-Week Range. Their latest funding was raised on Oct 12, 2022 from a Grant round. Analysts publish ratings. Vancouver, Canada. NervGen Pharma Corp. 13% Year to date 10. Company Overview; 1 Valuation;. NervGen Pharma Corp. stock was issued. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management will be presenting at two upcoming. NervGen Pharma Corp. Paradigm Capital delivered a healthcare sector update on Wednesday on drug developer NervGen Pharma ( NervGen Pharma Stock Quote, Charts, News, Analysts. According to present data NervGen Pharma's NGEN shares and potentially its market environment. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI),. 1. The stock has stayed mostly between $1 and $3 over that time period, with. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. 9800 +0. 39. 8 per cent over the course of the year, showing steady growth since bottoming out at $1. NervGen Pharma Corp. NervGen Pharma Corp. NervGen Pharma Corp. | 1,176 followers on LinkedIn. C. +1. announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to. NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury Association (ASIA) 50th Annual. The stock could jump quickly if the Company receives EU. - February 14, 2023) - NervGen Pharma Corp. 75. Get the latest NervGen Pharma Corp (NGENF) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. NervGen Pharma Corp. in funding over 7 rounds. Vancouver, British Columbia--(Newsfile Corp. The stock at $80 million mkt cap can 10 to 100 bag as. Loss and comprehensive loss - - - (4,967,595). Nov. NGENF | Complete NervGen Pharma Corp. Research NervGen Pharma's (TSXV:NGEN) stock key valuation metrics while comparing it with its industry peers & market side by side. NervGen Pharma Corp. NervGen Pharma Corp. 2022, compared to $1. Fair Ratio; Current PB Ratio: 15. Nov. Firm Analyst Encode Ideas, LP Hogan Mullally Paradigm Capital Scott McAuley, PhD NervGen Pharma Corp. - November 9, 2023) - NervGen Pharma Corp. September 5, 2023 – NervGen Pharma Corp. June 27, 2023. (TSX-V: NGEN;. 0164. View the latest NervGen Pharma Corp. News and Insights->->Vancouver, Canada. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 2022: CI NervGen Pharma Corp. 7200. 8 million as of September 30, 2023, compared to $22. View daily, weekly or monthly format back to when NervGen Pharma Corp. During the nine months ended September 30, 2022, we received proceeds of $2,957,761 from the exercise of stock options and common share purchase warrants. 3 million in proceeds from the exercise of options and warrants during. 21%) At close: 03:58PM EST. NervGen Pharma Grants Stock Options. stock forecast. NervGen began climbing after hitting a 52. Radvak has been the chief executive officer and director of multiple start-up companies. S. 4 per cent over the last 12 months, though investors who bought in to start 2022 have seen a 24. NervGen Pharma Corp. 0 million as of March 31, 2023. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce it has entered into a Memorandum of Understanding. July 22, 2020 — NervGen Pharma Corp. +1. The company’s lead target. A measure of how much a stock or commodity has risen or fallen over a one-year period. Vancouver, Canada--(Newsfile Corp. Mr. or […] NervGen Pharma Corp. Kelly exercisable at a price of $1. (NGEN:CA) stock. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial. Restoring Life's Potential by Creating Innovative Solutions for the Treatment of Nervous System Damage | NervGen is a publicly traded (TSX-V. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results. The decrease was primarily due to non-cash stock-based compensation expense related to option grants to employees and consultants, and the timing of the related vesting, partially offset by increases in legal, professional, and. 1. (the “Company” or “NervGen”) is a publicly traded. 1. 35 (1. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. 14. NervGen Pharma Corp. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease in which the immune system attacks myelin (the fatty coating around neurons) in the brain and spinal cord, damaging the neurons and impairing signal transmission. NervGen Pharma Announces Leadership Transition. 5 million as of December 31, 2022. October 25, 2022 – NervGen. Canadian clinical-stage biotech company, NervGen Pharma has enjoyed some positive results over the last few years. Vancouver, Canada. For instance, just consider the fact that Wall Street analysts are now estimating peak annual sales for Biogen’s new drug will range from $10 billion to $50 billion. 27: 52. - February 23, 2023) - NervGen Pharma Corp. The company’s lead target. NervGen Pharma press release (OTCQX:NGENF): Q3 GAAP EPS of -$0. Vancouver, British Columbia--(Newsfile Corp. Oct. 5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve InjuryNervGen Pharma (NGENF) will release its next earnings report on Nov 15, 2023. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. 78 per share for a period of 10 years and that vest equally every month over a three-year period. About NervGen . The company’s lead target. Stock-based compensation - - 633,953 - 633,953 Loss and comprehensive loss - - - (3,021,547) (3,021,547). As a revolutionary treatment for Alzheimer’s disease, alone, NVG-291, offers the potential to make NervGen a future star of the biotech sector. nancyt@vorticom. The company is developing drugs for the treatment of. (the "Company" or "NervGen") and should be read in conjunction with the accompanying consolidated financial statements and related notes thereto for the year ended December 31, 2021. NervGen Pharma Corp. Cash and investments of $18. Barchart. 064 USD Historical index on US Stock Market : A "Should I invest in NervGen Pharma stock?" "Should I trade "NGENF" stock today?" According to our live Forecast System,. AZO. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp. , through its subsidiary, NervGen US Inc. The 1-8 reverse split was announced on Friday, April 28th 2017. Description. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results. August 22, 2023. - February 28, 2022) - NervGen Pharma Corp. Loss and comprehensive loss - - - (4,967,595). The corporate office of the Company is located at 2955 Virtual Way, Suite 480, Vancouver, BC, V5M 4X6, Canada, and the registered office is located at Suite 2600,Vancouver, British Columbia--(Newsfile Corp. 2021 ANNUAL FINANCIAL STATEMENTS 5 1. NOT FOR DISTRIBUTION TO U. - May 18, 2023) - NervGen Pharma Corp. Overall, NervGen Pharma’s stock price has risen by 6. - August 8, 2023) - NervGen Pharma Corp. We advanced the clinical development of NVG-291. Firm Analyst Encode Ideas, LP Hogan Mullally Paradigm Capital Scott McAuley, PhD NervGen Pharma Corp. Today ||| 52-Week Range. (NGENF) stocks, the next step is researching the company. 81(+0. The price has risen in 6 of the last 10 days and is up by 4. The company’s lead target. August 9, 2023 at 5:30 AM · 10 min read. As a revolutionary treatment for Alzheimer’s disease, alone, NVG-291, offers the potential to make NervGen a future star of the biotech sector. , there are approximately 913,000 people living with MS 1 Rates of MS. CI. Stock Price & Overview 433 followers $1. All options, which will vest over two years, have been granted in accordance with the policies of the TSX Venture Exchange and the Company’s. NervGen Pharma Corp. October 27, 2021 - NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing. V) TSXV - TSXV Real Time Price. NervGen's lead drug candidate, NVG-291, is currently planned for a Phase 1b/2a clinical trial. chart to track its stock's price action. Corporate Communications (604) 537-2094. Bill Radvak is a co-founder and has been the Executive Chairman or Chairman of NervGen since its inception. finance. The latest NervGen Pharma stock prices, stock quotes, news, and NGENF. Newsfile Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. - October 25, 2022) - NervGen Pharma Corp. View real-time NGEN stock price and news, along with industry-best analysis. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. July 27, 2020 — NervGen Pharma Corp. NervGen Pharma is registered under the ticker OTCQB:NGENF . is a clinical-stage biotech company. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " or the " Company "), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public. Overall, NervGen Pharma’s stock price has risen by 6. 02:06:08 2021-04-01 pm EDT 5-day change 1st Jan Change. stock news by MarketWatch. The Company has also granted 2,892,000 incentive stock options to Mr. NervGen Pharma Corp. Get the latest NervGen Pharma Corp (NGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 23. The $1. EST Real Time Quote About NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. According to present data NervGen Pharma's NGEN shares and potentially its market environment have been in bearish cycle last 12 months (if exists). (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the first quarter ended March 31, 2023. If these results can be transferred to humans, it would be a milestone for many currently incurable diseases. Nervgen Pharma Corp. Stock After deciding where to buy NervGen Pharma Corp. 87%. V) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The NervGen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 Oct 27 NervGen Pharma Corp. - September 11, 2023) - NervGen Pharma Corp. 806 CAD. - December 15, 2020) - NervGen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 2022Cash and Investments: NervGen had cash and investments of $5. Multiple Sclerosis Facts and Figures In the U. NervGen Pharma Stock Prediction. The name was changed to NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a. - September 5, 2023) - NervGen Pharma Corp. 8 million as of September 30, compared to $22. Cash and investments of $18. - November 8, 2023) - NervGen Pharma Corp. May 15, 2023 – NervGen Pharma Corp. com. Nervgen Pharma Corp stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. 5 million as of December 31, 2022. - October 17, 2023) - NervGen Pharma Corp. Make Your Research on NervGen Pharma Corp. - October 27, 2021) - NervGen Pharma Corp. Vancouver, British Columbia-- (Newsfile Corp. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017, under the Business Corporations Act (British Columbia). Receives Up to $1. This is similarly the case for more than a million Americans who have debilitating peripheral nerve injuries. -1. Share your opinion and gain insight from other stock traders and investors. Trending Stocks Technical Analysis Screener Penny Stock Screener Daily Analyst Ratings Daily Insider Trading Tracker. 0 million as of March 31, 2023 Vancouver, Canada. A high-level overview of NervGen Pharma Corp. S. View the latest NervGen Pharma Corp. Kelly currently serves on the Board of Directors of ARS Pharmaceuticals, which he joined in May 2019. It is currently in Phase 1 FDA trials in humans and is about to go into Phase 2. 0015 (+0. - May 15, 2023) - NervGen Pharma Corp. See the latest NervGen Pharma Corp Ordinary Shares stock price (NGENF:PINX),. This was offset by approximately $2. Vancouver, Canada. As of Nov 01. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. stock indexes jumped more than 1% Tuesday morning, with the coming close to a 2% gain. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results. 2. Delayed Data. Description. The corporate office of the Company is located atNervGen Pharma Corp. Cash Markets Overview Corn Indexes Soybean Indexes Wheat Indexes Energies Indexes Yield Forecast Indexes. 1. The following discussion is management's assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. . A high-level overview of NervGen Pharma Corp. Complete NervGen Pharma Corp. 1 million in proceeds from the exercise of. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical. 2021 ANNUAL FINANCIAL STATEMENTS 5 1. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 12, 2021 – NervGen Pharma Corp. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later. (NGEN. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. 0015 (+0. August 4, 2020 — NervGen Pharma Corp. The Company has granted 800,000 incentive stock options exercisable at a price of $3. He was a founder and the CEO of Response Biomedical Corp. 07. Vancouver, Canada. Read more. announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to. NervGen Pharma Corp. 2022, we received $2,722,463 from the exercise of stock options and Common Share Purchase Warrants. Vancouver, British Columbia--(Newsfile Corp. 1 million in proceeds from the exercise of stock options and warrants during the year and a non-brokered private placement for gross. 2023-04-10 09:44 ET - News Release. yahoo. (the “Company” or “NervGen”) is a publicly traded. Nervgen Pharma Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Vancouver, Canada. 0100 (-0. C. S. 14: CI Nervgen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, today announced that the Company has granted. Department of Defense and PFP Biosciences are the most recent investors. 30/share on May 31, but not quite reaching the high. 30/share on May 31, but not quite reaching the high. NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Completed NVG-291 dosing of subjects in Phase 1 clinical trial Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023 NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticity Vancouver, Canada. 295$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). Huitt Tracey. 0 million as of March 31, 2023, compared to $22. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing. Vancouver, Canada. ; NervGen had cash and investments of $22. - November 27, 2019) - NervGen Pharma Corp. 19%) Crude Oil 76. 34,947. stock information by Barron's. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or. Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - NervGen Pharma Corp. Nature of business NervGen Pharma Corp. Get the latest NervGen Pharma Corp. Vancouver, Canada. NervGen Pharma press release (OTCQX:NGENF): Q3 GAAP EPS of -$0. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. This was offset by approximately $0. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system. For more information. 03% Nov 21, 2023 3:59 p. See the latest NervGen Pharma Corp Ordinary Shares stock price (NGENF:PINX),. Vancouver - NervGen Pharma Corp. - April 6, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial results for the third quarter ended September 30, 2022 and provided an operational update. - September 8, 2022) - NervGen Pharma Corp. For NervGen Pharma, we've compiled three additional factors you should further research: Risks : Be aware that NervGen Pharma is showing 5 warning signs in our investment analysis , and 3 of those. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury CINervGen Pharma (NervGen Pharma Stock Quote, Charts, News, Analysts, Financials TSXV:NGEN) Rating: Speculative Buy Target Price: $6. 1. — NervGen Pharma Corp. The company’s lead target. 48 +11. Alnylam Pharmaceuticals Inc: Kkvsytx: $20. The Company also announced that it has granted 150,000 incentive stock options to Mr. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval View Release « Previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Next » NervGen Pharma has a market capitalisation of CA$114m and burnt through CA$17m last year, which is 15% of the company's market value. What this means: InvestorsObserver gives Nervgen Pharma Corp (NGENF) an overall rank of 32, which is below average. - November 12, 2021) - NervGen Pharma Corp. announced the formation of its Multiple Sclerosis Clinical Advisory Board comprised of six world-class scientific and clinical researchers in the field of multiple sclerosis:. Vancouver, British Columbia-- (Newsfile Corp. holds the exclusive worldwide rights to NVG-291, and the drug is also currently being tested in a Phase 1 clinical trial in healthy human subjects. 32; its P/E ratio is -5. What this means: InvestorsObserver gives Nervgen Pharma Corp (NGENF) an overall rank of 32, which is below average. August 10, 2020 — NervGen Pharma Corp. m. In the last quarter NervGen Pharma reported ― EPS in relation to -$0. 75 per share for a period of three years and that vest 25% per quarter. : Forcasts, revenue, earnings, analysts expectations, ratios for NervGen Pharma Corp. About NervGen. Vancouver, British Columbia--(Newsfile Corp. “We. Chronic spinal cord injury cohort results expected in mid-2024 ; Subacute spinal cord injury cohort results expected in late 2024/early 2025; Vancouver, British Columbia--(Newsfile Corp. Analyst Forecast According to 8 analysts, the average rating for AMAM stock is "Buy. 75 per share for a period of five years and that vest equally every three months over a one-year period. The net cash burn for Q3 2023 from operating and investing activities was approximately $1. - February 28, 2022) - NervGen Pharma Corp. The corporate office of the Company is located atNervGen Pharma Corp. NervGen's lead drug candidate, NVG-291, is currently planned to be evaluated in a Phase 1b/2a clinical trial. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself. was tempered with the announcement of a slow growth forecast ahead. Vancouver, British Columbia--(Newsfile Corp. Russell 2000 Futures 1,736. NervGen Pharma Corp. 2022, we received $2,722,463 from the exercise of stock options and Common Share Purchase Warrants. This was offset by approximately $0. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock. Vancouver - NervGen Pharma Corp. Michael Kelly to the position of President & CEO effective April 10, 2023. 0164 / +1. 10% most volatile stocks in CA Market. Vancouver, Canada. 33, which is within the analyst’s predicted range. 0 Bil: INCY NGENF Nervgen Consolidation continues Possible entry ahead Nice long ~2 year consolidation is in progress, recent reject from the top side of wedge will present entry opportunities Entry target ~ 1. 620 CAD 7 Days Forecast Get It Now! 1-Year Forecast * 1. The Company's initial target indication is spinal cord injury. Currency in CAD. 10. July 14, 2022 at 9:05 AM · 10 min read. NERVGEN PHARMA CORP. Vancouver, British Columbia--(Newsfile Corp. operates as a regenerative medicine.